News Novartis nabs cardio drug with $1.4bn Tourmaline buy Novartis has bulked up in cardiology with a $1.4bn takeover of Tourmaline Bio and its drug for atherosclerotic cardiovascular disease (ASCVD).
News Novartis pens $5.2bn cardiovascular partnership with Argo Novartis is paying $160m upfront to activate an expanded R&D alliance with China's Argo Biopharma covering multiple cardiovascular disease drugs.
News Lilly raises stakes in Novartis battle with Verzenio data Armed with new survival data for Verzenio in early breast cancer, Lilly hopes to keep the drug's nose in front of a fast-growing rival from Novartis.
News Novartis taps Atropos AI for earlier PNH diagnoses Novartis teams up with real-world evidence specialist Atropos Health, hoping to speed up the diagnosis and treatment of rare disease PNH.
News Novartis two for two as ianalumab scores again Novartis' ianalumab has delivered another win in primary immune thrombocytopenia, its second win in autoimmune diseases in 24 hours.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
